Literature DB >> 11174469

Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up.

M M Zweers1, D G Struijk, W Smit, R T Krediet.   

Abstract

In a previous study, vascular endothelial growth factor (VEGF) was found to be locally produced in the peritoneal tissue of patients undergoing peritoneal dialysis (PD) who were being treated with glucose-containing PD solutions. Locally produced VEGF (LVEGF) was positively related to the mass transfer area coefficient (MTAC) of creatinine and to glucose absorption, both of which are representative of the peritoneal vascular surface area. It was therefore hypothesized that VEGF is involved in the peritoneal neoangiogenesis found in long-term PD. The aim of the present study was to investigate the time course of peritoneal VEGF levels in PD patients treated with glucose-based PD solutions during longitudinal follow-up. We also studied the effect of the switch to glucose-free PD treatment on VEGF production. Forty standard peritoneal permeability analyses (SPAs) with 3.86% glucose-containing dialysis solution were investigated. The SPAs were performed in 10 PD patients with a median number of three SPAs per patient during a follow-up of 23 months. Duration of PD treatment at the last SPA was 74 months. All patients were initially treated with glucose-containing dialysis solutions. Four patients switched after 114 months of glucose-based PD to glucose-free PD and were followed for 7 months. A PD regimen of icodextrin, glycerol, and amino acid-based dialysis solutions was applied in these patients. Four SPAs were performed per patient in this period. To predict the VEGF dialysate-to-serum ratio (D/S), when diffusion would be the only explanation for the VEGF dialysate concentration, we calculated the power relationship between D/S ratios of serum proteins that are only transported across the peritoneum and the molecular weights of those proteins. The measured VEGF D/S ratio was higher than expected (P <.001) in each observation, pointing to local production of VEGF. LVEGF increased with duration of glucose PD, 11.7 ng/L to 23.45 ng/L (P <.03). LVEGF decreased in all 4 patients undergoing glucose-free PD, from 57.35 ng/L to 23.10 ng/L. A correlation (r = 0.83, P <.001) was found be-tween the differences in MTAC creatinine between the first and last SPA during glucose-based PD and the difference in LVEGF between these observations. A similar correlation was present between the difference in glucose absorption and the difference in LVEGF (r = 0.85, P <.001). This supports a pathogenetic role of high glucose dialysate concentrations in the development of changes in the peritoneum that are found in long-term PD. Treatment with non-glucose-based PD solutions may inhibit further development of these alterations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11174469     DOI: 10.1067/mlc.2001.112235

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  22 in total

1.  The solution to better preservation of the peritoneal membrane still lies hidden in the solution.

Authors:  Dirk G Struijk
Journal:  Perit Dial Int       Date:  2015 Mar-Apr       Impact factor: 1.756

Review 2.  Strategies for preventing peritoneal fibrosis in peritoneal dialysis patients: new insights based on peritoneal inflammation and angiogenesis.

Authors:  Zhen Zhang; Na Jiang; Zhaohui Ni
Journal:  Front Med       Date:  2017-08-08       Impact factor: 4.592

Review 3.  Encapsulating peritoneal sclerosis: the state of affairs.

Authors:  Mario R Korte; Denise E Sampimon; Michiel G H Betjes; Raymond T Krediet
Journal:  Nat Rev Nephrol       Date:  2011-08-02       Impact factor: 28.314

Review 4.  Peritoneal changes in patients on long-term peritoneal dialysis.

Authors:  Raymond T Krediet; Dirk G Struijk
Journal:  Nat Rev Nephrol       Date:  2013-05-14       Impact factor: 28.314

5.  The abnormal expressions of tristetraprolin and the VEGF family in uraemic rats with peritoneal dialysis.

Authors:  Jing Xiao; Huanhuan Gao; Yunfeng Jin; Zhihong Zhao; Jia Guo; Zhangsuo Liu; Zhanzheng Zhao
Journal:  Mol Cell Biochem       Date:  2014-04-03       Impact factor: 3.396

6.  Prolonged use of the tyrosine kinase inhibitor in a peritoneal dialysis patient with metastatic renal cell carcinoma: possible beneficial effects on peritoneal membrane and peritonitis rates.

Authors:  Shruti N Tapiawala; Joanne M Bargman; Dimitrios G Oreopoulos; Martin Simons
Journal:  Int Urol Nephrol       Date:  2009-03-03       Impact factor: 2.370

7.  Thalidomide prevents the progression of peritoneal fibrosis in mice.

Authors:  Hideyuki Arai; Akira Furusu; Tomoya Nishino; Yoko Obata; Yuka Nakazawa; Masayuki Nakazawa; Misaki Hirose; Katsushige Abe; Takehiko Koji; Shigeru Kohno
Journal:  Acta Histochem Cytochem       Date:  2011-04-21       Impact factor: 1.938

8.  Effluent markers related to epithelial mesenchymal transition with adjusted values for effluent cancer antigen 125 in peritoneal dialysis patients.

Authors:  Sonoo Mizuiri; Hiromichi Hemmi; Michitsune Arita; Reibin Tai; Yoshinari Hattori; Atsuhiko Muto; Yasunori Suzuki; Yasushi Ohashi; Ken Sakai; Atsushi Aikawa
Journal:  Int J Nephrol       Date:  2011-07-06

9.  Are the Mesothelial-to-Mesenchymal Transition, Sclerotic Peritonitis Syndromes, and Encapsulating Peritoneal Sclerosis Part of the Same Process?

Authors:  Jesús Loureiro; Guadalupe Gónzalez-Mateo; José Jimenez-Heffernan; Rafael Selgas; Manuel López-Cabrera; Abelardo Aguilera Peralta
Journal:  Int J Nephrol       Date:  2013-02-10

Review 10.  Pathophysiological changes to the peritoneal membrane during PD-related peritonitis: the role of mesothelial cells.

Authors:  Susan Yung; Tak Mao Chan
Journal:  Mediators Inflamm       Date:  2012-04-10       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.